Looks like Meta is hoping the recent Supreme Court ruling that found Internet service providers aren't liable for piracy on their networks will help the social media giant dodge liability claims over its torrenting of AI training data . Last week, Meta filed a statement in a lawsuit that alleged that Meta should be liable under copyright law for contributory infringement simply because the company...
Looks like Meta is hoping the recent Supreme Court ruling that found Internet service providers aren't liable for piracy on their networks will help the social media giant dodge liability claims over its torrenting of AI training data . Last week, Meta filed a statement in a lawsuit that alleged that Meta should be liable under copyright law for contributory infringement simply because the company knows how torrenting works. By seeding perhaps 80 terabytes of pirated works, the company allegedly knew it was inducing infringement by allowing uploads to help speed up its downloads, the plaintiffs, Entrepreneur Media, argued. This contributory infringement claim is much easier to prove than a separate claim raised in a class action filed by book authors in Kadrey v. Meta , which alleged that Meta's torrenting meant it was liable for a "distribution" claim of direct copyright infringement. TorrentFreak noted that the authors' claim required evidence that Meta torrented an entire work, whereas the contributory infringement claim only depends on proving that Meta facilitated torrent transfers. Read full article Comments
Dilok Klaisataporn/iStock via Getty Images I started studying economics and finance in 2019, and one of the first things that I learned was that equities tend to have a negative correlation with bonds. Therefore, if you add bonds to your equity portfolio, you are essentially hedging against the downside risk. In theory, if a recession occurs, equities drop, but part of the losses are going to be o...
Dilok Klaisataporn/iStock via Getty Images I started studying economics and finance in 2019, and one of the first things that I learned was that equities tend to have a negative correlation with bonds. Therefore, if you add bonds to your equity portfolio, you are essentially hedging against the downside risk. In theory, if a recession occurs, equities drop, but part of the losses are going to be offset by bond price appreciation. So, if a 100% equity portfolio drops 40% during a severe recession, a 60/40 (60% equities, 40% bonds) portfolio might decline by just 15-20%. For years, financial advisors promoted the 60/40 portfolio as a way to benefit from bullish periods while reducing your downside risk, but I believe that this strategy no longer works. Why? Because the correlation between bonds and equity is no longer negative. In my opinion, bonds won’t protect you against the next recession. Where Does This Bias Come From? To understand why the 60/40 portfolio no longer works to protect you against the downside risk, I believe it is important to first point out why it got so popular. People love the idea of remaining invested in the stock market while taking less risk thanks to the bond’s exposure. The 60/40 portfolio was the ideal compromise for people with a low-medium risk tolerance, and the performance achieved across the “lost decade” further fueled their conviction. Lost decade returns (Kaplan Ibbotson) From 2001 to 2013, the stock market (red line) went nowhere because the US economy faced two significant recessions. But the 60/40 portfolio (blue line) was up about 30% during the same period. Not only that, in fact the downsides were much less pronounced, something that is very important to help you not panic. After such a great performance during one of the worst periods ever to be invested, it is not a coincidence that the 60/40 portfolio started to gain weight in the financial community. In 2011, Vanguard launched LifeStrategy 60/40, basically an ETF that ...
In trading on Monday, shares of Pennymac Mortgage Investment Trust's 8.125% Series A Fixed-to-Floating Rate Cumulative Redeemable Preferred Shares of Beneficial Interest (Symbol: PMT.PRA) were yielding above the 9% mark based on its quarterly dividend (annualized to $2.0313), wi
In trading on Monday, shares of Pennymac Mortgage Investment Trust's 8.125% Series A Fixed-to-Floating Rate Cumulative Redeemable Preferred Shares of Beneficial Interest (Symbol: PMT.PRA) were yielding above the 9% mark based on its quarterly dividend (annualized to $2.0313), wi
In trading on Monday, shares of Nexpoint Diversified Real Estate Trust's 5.50% Series A Preferred Shares (Symbol: NXDT.PRA) were yielding above the 10.5% mark based on its quarterly dividend (annualized to $1.375), with shares changing hands as low as $13.09 on the day. This
In trading on Monday, shares of Nexpoint Diversified Real Estate Trust's 5.50% Series A Preferred Shares (Symbol: NXDT.PRA) were yielding above the 10.5% mark based on its quarterly dividend (annualized to $1.375), with shares changing hands as low as $13.09 on the day. This
You work hard. You pay your taxes. It seems like you're doing everything you can to maximize your Social Security benefits in retirement. But there could be a few things you're still overlooking. If you truly want to get the most out of the program, there are three key parts of the Social Security benefit formula you must learn to leverage. Here's what you need to do. Image source: Getty Images. C...
You work hard. You pay your taxes. It seems like you're doing everything you can to maximize your Social Security benefits in retirement. But there could be a few things you're still overlooking. If you truly want to get the most out of the program, there are three key parts of the Social Security benefit formula you must learn to leverage. Here's what you need to do. Image source: Getty Images. Continue reading
Recent legal blows have pushed META stock into “oversold” territory. But Morgan Stanley continues to see META shares as a “top pick” for the remainder for 2026.
Recent legal blows have pushed META stock into “oversold” territory. But Morgan Stanley continues to see META shares as a “top pick” for the remainder for 2026.
Key PointsAtwell exercised 10,000 options and sold 3,331 Common Stock shares on March 5, 2026, for a transaction value of ~$502,000 at a weighted average price of around $150.67 per share.
Key PointsAtwell exercised 10,000 options and sold 3,331 Common Stock shares on March 5, 2026, for a transaction value of ~$502,000 at a weighted average price of around $150.67 per share.
Pornpimone Audkamkong/iStock via Getty Images By Mandy Xu Cross-Asset Volatility: Implied volatilities gained across asset classes last week as the Iran war dragged into its fourth week. Oil volatility increased, with WTI 1M implied vol up 10 pts to 81% on the back of continued demand for upside calls as traders positioned for potential prolonged disruption to oil supply. Gold volatility jumped hi...
Pornpimone Audkamkong/iStock via Getty Images By Mandy Xu Cross-Asset Volatility: Implied volatilities gained across asset classes last week as the Iran war dragged into its fourth week. Oil volatility increased, with WTI 1M implied vol up 10 pts to 81% on the back of continued demand for upside calls as traders positioned for potential prolonged disruption to oil supply. Gold volatility jumped higher, with GLD 1M implied vol increasing over 9 pts to near a 5-year high of 41%. As we highlighted last week, positioning in gold options has shifted notably, with demand for puts picking up in recent weeks amidst the geopolitical turmoil. GLD 1M skew (25-delta ratio) has steepened to almost a 10-year high after being persistently inverted for most of the past two years. Rates volatility gained modestly as traders weighed the higher inflation backdrop with the hit to the growth outlook, while credit volatility continued its upward climb. VIXHY Index has more than tripled since the beginning of the year to a high of 320 bps vol – higher than the Q4 2018 growth scare (when SPX Index sold off 20%). Equity Volatility: The VIX Index jumped 4.3 pts to 31% last week, ending the week at its highest level since last year’s April sell-off. Notably, however, there’s been very little panic in the options market. Even when SPX Index fell 3.4% on Thu/Fri, the bid to volatility came more from the upside than the downside as investors positioned for a potential rebound (aka “the TACO Trade”). In fact, put skew and put convexity both declined as investors used the pullback to monetize existing hedges. SPX 1M put skew (25-delta vs. 50-delta ratio) has now fallen to near a 1-year low (2nd percentile over the past year). Instead, we saw demand for upside calls pick up going into the weekend, adding almost 2 pts to the 5.7 pt increase in the VIX Index on Thu/Fri. See Exhibit 2. Will the “TACO Trade” work this time? The optimism in the equity options market contrasts with the caution we’re seei...
JHVEPhoto New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of l ow-density lipoprotein cholesterol (LDL-C) compared to oral non-statin medicines. The CORALreef AddOn study compared enlicitide to ezetimibe, Esperion Therapeutics' ( ESPR ) Nexletol (bempedoic acid), and a combination of the two drugs. At eight weeks, enlicitide reduced LDL-C by ...
JHVEPhoto New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of l ow-density lipoprotein cholesterol (LDL-C) compared to oral non-statin medicines. The CORALreef AddOn study compared enlicitide to ezetimibe, Esperion Therapeutics' ( ESPR ) Nexletol (bempedoic acid), and a combination of the two drugs. At eight weeks, enlicitide reduced LDL-C by 64.6% from baseline when added to statin treatment. Other data showed that enlicitide cut LDL-C by 56.7% versus bempedoic acid; 36% versus ezetimibe; and 28.1% versus bempedoic acid with ezetimibe. Secondary endpoints, such as reductions in apolipoprotein B and non-high-density lipoprotein cholesterol vs. bempedoic acid, ezetimibe, and bempedoic acid/ezetimibe, were also met. In December, enlicitide was granted an FDA Commissioner National Priority Voucher. While two PCSK9 inhibitors are already marketed—Amgen's ( AMGN ) Repatha (evolocumab) and Regeneron Pharmaceuticals' ( REGN ) Praluent (alirocumab)—they are both given via injection. More on Merck Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business Merck & Co., Inc. (MRK) M&A Call Transcript Former CDC advisor says White House pulling back on vaccine policy Anti-vaccine group asks RFK Jr. to add more vaccine injuries to compensation program